Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) ...
Clinical Trials Arena on MSN
Ipsen set to rival Botox after duo of Phase III migraine wins
The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.
The Botox injections that smooth wrinkles rely on the ability of botulinum toxins from the bacterium Clostridium botulinum to block communication between cells. In the cosmetic treatment, these toxins ...
The botulinum toxins are among the deadliest substances on Earth, and two specific toxins -- including the popular drug Botox -- have multiple uses for treating many neuromuscular conditions, ...
A team of researchers from the University of California, Irvine, have revealed the first crystal structures of the receptor-binding domain of botulinum neurotoxin E (BoNT/E) in complex with its human ...
Figure 3: Site-directed mutagenesis analysis of the toxin-receptor binding site in BoNT/B and in the luminal domains of Syt-I and Syt-II. Figure 4: Simultaneous binding with membrane-anchored Syt-II ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results